CA1293928C - Thermofiltration de plasma - Google Patents

Thermofiltration de plasma

Info

Publication number: CA1293928C
Authority: CA; Canada
Prior art keywords: plasma; stream; macromolecules; solution; temperature
Prior art date: 1985-12-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA000525261A

Other languages

English (en)

Inventor

Yukihiko Nose

Paul S. Malchesky

Takashi Horiuchi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cleveland Clinic Foundation

Original Assignee

Cleveland Clinic Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-12-19

Filing date

1986-12-12

Publication date

1992-01-07

1986-12-12 Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation

1992-01-07 Application granted granted Critical

1992-01-07 Publication of CA1293928C publication Critical patent/CA1293928C/fr

2009-01-07 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000000034 method Methods 0.000 claims abstract description 72
229920002521 macromolecule Polymers 0.000 claims abstract description 61
239000012528 membrane Substances 0.000 claims abstract description 23
238000009835 boiling Methods 0.000 claims abstract description 18
230000036760 body temperature Effects 0.000 claims abstract description 16
238000001914 filtration Methods 0.000 claims description 49
108010007622 LDL Lipoproteins Proteins 0.000 claims description 41
102000007330 LDL Lipoproteins Human genes 0.000 claims description 41
238000007873 sieving Methods 0.000 claims description 35
238000010438 heat treatment Methods 0.000 claims description 21
230000001413 cellular effect Effects 0.000 claims description 17
102000004169 proteins and genes Human genes 0.000 claims description 13
108090000623 proteins and genes Proteins 0.000 claims description 13
238000000926 separation method Methods 0.000 claims description 12
241000282465 Canis Species 0.000 claims description 10
210000004369 blood Anatomy 0.000 claims description 10
239000008280 blood Substances 0.000 claims description 10
230000017531 blood circulation Effects 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 10
108010042158 Pyroglobulins Proteins 0.000 claims description 9
239000012530 fluid Substances 0.000 claims description 8
241000282414 Homo sapiens Species 0.000 claims description 7
230000008569 process Effects 0.000 claims description 7
208000035150 Hypercholesterolemia Diseases 0.000 claims description 6
206010008609 Cholangitis sclerosing Diseases 0.000 claims description 5
208000010157 sclerosing cholangitis Diseases 0.000 claims description 5
238000001816 cooling Methods 0.000 claims description 4
238000005086 pumping Methods 0.000 claims 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 144
210000002381 plasma Anatomy 0.000 description 135
235000012000 cholesterol Nutrition 0.000 description 66
108010088751 Albumins Proteins 0.000 description 22
102000009027 Albumins Human genes 0.000 description 22
238000000338 in vitro Methods 0.000 description 20
239000000243 solution Substances 0.000 description 17
241000282472 Canis lupus familiaris Species 0.000 description 16
238000008214 LDL Cholesterol Methods 0.000 description 15
102000004895 Lipoproteins Human genes 0.000 description 13
108090001030 Lipoproteins Proteins 0.000 description 13
229920000669 heparin Polymers 0.000 description 10
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 9
229960002897 heparin Drugs 0.000 description 9
238000012360 testing method Methods 0.000 description 9
150000002500 ions Chemical class 0.000 description 8
238000011282 treatment Methods 0.000 description 8
239000002245 particle Substances 0.000 description 7
238000011084 recovery Methods 0.000 description 7
238000004458 analytical method Methods 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
235000005911 diet Nutrition 0.000 description 6
230000037213 diet Effects 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000011148 porous material Substances 0.000 description 6
102000008946 Fibrinogen Human genes 0.000 description 5
108010049003 Fibrinogen Proteins 0.000 description 5
239000000495 cryogel Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
229940012952 fibrinogen Drugs 0.000 description 5
238000001556 precipitation Methods 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
230000008901 benefit Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
102000004411 Antithrombin III Human genes 0.000 description 3
108090000935 Antithrombin III Proteins 0.000 description 3
208000033522 Proximal spinal muscular atrophy type 2 Diseases 0.000 description 3
229960005348 antithrombin iii Drugs 0.000 description 3
230000004087 circulation Effects 0.000 description 3
201000006913 intermediate spinal muscular atrophy Diseases 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
238000005374 membrane filtration Methods 0.000 description 3
235000021590 normal diet Nutrition 0.000 description 3
230000009467 reduction Effects 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
208000032521 type II spinal muscular atrophy Diseases 0.000 description 3
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
239000004380 Cholic acid Substances 0.000 description 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
239000005977 Ethylene Substances 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
238000011325 biochemical measurement Methods 0.000 description 2
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
229960002471 cholic acid Drugs 0.000 description 2
235000019416 cholic acid Nutrition 0.000 description 2
235000019864 coconut oil Nutrition 0.000 description 2
239000003240 coconut oil Substances 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000011833 dog model Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000009832 plasma treatment Methods 0.000 description 2
-1 polypropylene Polymers 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
206010008635 Cholestasis Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
101000797262 Mus musculus N-acyl-aromatic-L-amino acid amidohydrolase (carboxylate-forming) Proteins 0.000 description 1
101100006310 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chol-1 gene Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920000297 Rayon Polymers 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108010045362 Serum Globulins Proteins 0.000 description 1
102000005686 Serum Globulins Human genes 0.000 description 1
206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
108010069201 VLDL Cholesterol Proteins 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
208000003167 cholangitis Diseases 0.000 description 1
230000007870 cholestasis Effects 0.000 description 1
231100000359 cholestasis Toxicity 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
229940002658 differin Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000008151 electrolyte solution Substances 0.000 description 1
229940021013 electrolyte solution Drugs 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
201000001386 familial hypercholesterolemia Diseases 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000003890 fistula Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229960001008 heparin sodium Drugs 0.000 description 1
230000000260 hypercholesteremic effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
108010022197 lipoprotein cholesterol Proteins 0.000 description 1
230000001589 lymphoproliferative effect Effects 0.000 description 1
201000000564 macroglobulinemia Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
238000002616 plasmapheresis Methods 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000002964 rayon Substances 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
230000002277 temperature effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000010792 warming Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/369—Temperature treatment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3482—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/18—Apparatus therefor
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/22—Cooling or heating elements
- B01D2313/221—Heat exchangers

Landscapes

Health & Medical Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Engineering & Computer Science (AREA)
Vascular Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Anesthesiology (AREA)
Cardiology (AREA)
Water Supply & Treatment (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
External Artificial Organs (AREA)
Separation Using Semi-Permeable Membranes (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

CA000525261A 1985-12-19 1986-12-12 Thermofiltration de plasma Expired - Fee Related CA1293928C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US81092685A	1985-12-19	1985-12-19
US810,926		1985-12-19

Publications (1)

Publication Number	Publication Date
CA1293928C true CA1293928C (fr)	1992-01-07

Family

ID=25205058

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000525261A Expired - Fee Related CA1293928C (fr)	1985-12-19	1986-12-12	Thermofiltration de plasma

Country Status (7)

Country	Link
JP (1)	JPS62150163A (fr)
CA (1)	CA1293928C (fr)
DE (1)	DE3643348A1 (fr)
FR (1)	FR2591901A1 (fr)
GB (1)	GB2184670A (fr)
IT (1)	IT1199792B (fr)
SE (1)	SE8605291L (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN2698358Y (zh) *	2004-04-06	2005-05-11	上海江夏血液技术有限公司	血液过滤装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2411239A (en) *	1943-07-08	1946-11-19	Sylvania Ind Corp	Apparatus for dialyzing
NL238400A (fr) *	1958-04-21
JPS52155888A (en) *	1976-06-22	1977-12-24	Mitsui Toatsu Chemicals	Device for continuously removing material in blood flow
CA1119971A (fr) *	1976-09-07	1982-03-16	James T. Hutchisson	Appareil d'hemodialyse avec collecteur modulaire pour le dialysat
US4350156A (en) *	1980-05-29	1982-09-21	Japan Foundation For Artificial Organs	Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid

1986
- 1986-12-10 SE SE8605291A patent/SE8605291L/xx not_active Application Discontinuation
- 1986-12-12 CA CA000525261A patent/CA1293928C/fr not_active Expired - Fee Related
- 1986-12-15 FR FR8617508A patent/FR2591901A1/fr active Pending
- 1986-12-16 IT IT22715/86A patent/IT1199792B/it active
- 1986-12-16 GB GB08630034A patent/GB2184670A/en not_active Withdrawn
- 1986-12-18 JP JP61300206A patent/JPS62150163A/ja active Pending
- 1986-12-18 DE DE19863643348 patent/DE3643348A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
DE3643348A1 (de)	1987-06-25
SE8605291L (sv)	1987-06-20
IT8622715A0 (it)	1986-12-16
IT1199792B (it)	1988-12-30
JPS62150163A (ja)	1987-07-04
FR2591901A1 (fr)	1987-06-26
SE8605291D0 (sv)	1986-12-10
GB2184670A (en)	1987-07-01
GB8630034D0 (en)	1987-01-28

Legal Events

Date	Code	Title	Description
1994-07-09	MKLA	Lapsed

Publication	Publication Date	Title
US4966709A (en)	1990-10-30	Thermofiltration of plasma
US5080796A (en)	1992-01-14	Thermofiltration of plasma
US4350156A (en)	1982-09-21	Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
Yokoyama et al.	1985	Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia.
US4648974A (en)	1987-03-10	Process for the selective extracorporeal separation of blood constituents
EP0166325B1 (fr)	1989-11-23	Procédé et appareil pour la séparation sélective des éléments pathologiques et/ou toxiques du sang ou du plasma par l'utilisation de filtres en forme de bougie
GB1562546A (en)	1980-03-12	Removing specific factors from blood
Nosé et al.	1985	Clinical thermofiltration: initial application
US5217618A (en)	1993-06-08	Plasma purification treatment
Ronco et al.	1996	Basic mechanisms and definitions for continuous renal replacement therapies
CA1293928C (fr)	1992-01-07	Thermofiltration de plasma
Castino et al.	1978	The filtration of plasma from whole blood: A novel approach to clinical detoxification
Malchesky et al.	1986	Blood detoxification by membrane plasma filtration
JPH0211263B2 (fr)	1990-03-13
Nosé et al.	2000	Therapeutic membrane plasmapheresis
JPH1057476A (ja)	1998-03-03	膜分離装置
Malchesky	1996	8.3 EXTRACORPOREAL ARTIFICIAL ORGANS
Ryan et al.	1986	Repeated membrane plasma separation with on‐line sorbent treatment of plasma in the conscious rat
JPS6362B2 (fr)	1988-01-05
Horiuchi et al.	1987	Plasma Protein Fractionation by Membrane Filtration in Therapeutic Plasmapheresis
Takeyama et al.	1988	Removal and recovery of cholesterol in thermofiltration
Nosé et al.	1981	Augmented solute reduction in diseases treated by extracorporeal detoxification systems: X-effect hypothesis
Smith et al.	1984	Membrane plasmapheresis and the developing technology of plasma therapy
Olson et al.	1977	Rapid delipidation of and particulate removal from human serum by membrane filtration in a tangential flow system
CA1176573A (fr)	1984-10-23	Methode et appareil pour l'enlevement continu par filtration de macromolecules dans un liquide physiologique